What Cafergot Tablets Treats: Main Uses and Benefits

---

The combination of ergotamine and caffeine, known as Cafergot, is a specialized medication applied for the management of severe headache symptoms. This medication is commonly used to help with and manage migraine headaches.

Therapeutic Focus and Benefit

Cafergot is applied as an abortive therapy for the acute treatment of established migraine headaches, including those with or without an aura. Its primary purpose is to provide supportive relief that helps ease the severe, intense, and throbbing pain characteristic of these vascular headache attacks. The primary indications involve the acute treatment of severe migraine, managing debilitating symptom severity, and serving as rescue support in challenging clinical scenarios.

This medication is relevant for managing episodes where the pain severity is debilitating and significantly interferes with daily function. It is intended to assist with maintaining functional stability during phases of sudden symptom escalation, particularly when symptoms create noticeable physiological strain and supportive symptomatic management is appropriate.

---

“This approach is relevant when symptoms become temporarily overwhelming and short-term symptomatic assistance is needed.”

---

Quick Fact: Relief for Vascular Head Pain	Property	Description
Therapeutic Role	Abortive therapy (used to interrupt attacks)
Symptom Focus	Severe, throbbing head pain
Primary Indication	Acute migraine headaches
Usage Context	Rescue support for debilitating episodes

Regulatory References

1. Ergotamine and Caffeine: MedlinePlus Drug Information

Who Can and Cannot Use Cafergot Tablets?

This section outlines the official eligibility and non-eligibility requirements for Cafergot (ergotamine tartrate and caffeine) based strictly on government regulatory documents.

---

Official Contraindications

Cafergot is absolutely contraindicated for use in several populations to prevent serious health risks, primarily due to the potent vasoconstrictive effects of ergotamine:

• Cardiovascular Conditions: Individuals with coronary heart disease, peripheral vascular disease, or uncontrolled high blood pressure (hypertension).
• Organ Function: Patients with severe liver (hepatic) or severe kidney (renal) impairment.
• Reproductive Status: Women who are pregnant or may become pregnant, and women who are breastfeeding.
• Concomitant Use: Patients currently taking potent CYP 3A4 inhibitors (such as certain macrolide antibiotics or HIV protease inhibitors) or other vasoconstrictor agents (e.g., triptans or other ergot-containing medicines).
• Other Conditions: Patients with sepsis or severe infectious states, hyperthyroidism, or a known hypersensitivity to any component.

---

Restricted and Non-Recommended Use

• Age: Use is not recommended for the paediatric population (under 18 years) or for geriatric patients (over 65 years), as safety and effectiveness have not been established in these age groups.
• Administration: The medicine is not to be used for chronic daily administration or long-term continuous treatment.
• Comorbidities: Caution and appropriate monitoring are required for patients with mild to moderate hepatic impairment.

Cafergot Tablets Interactions with other medicines and products

Officially documented interactions for this combination product fall under two primary regulatory constraints: pharmacokinetic inhibition and pharmacodynamic synergism. Co-administration with certain medicinal products is strictly prohibited, as defined by government regulatory authorities.

Contraindicated Combinations

The combination is contraindicated with potent inhibitors of the CYP3A4 enzyme, which prevent the clearance of the ergotamine component. This pharmacokinetic interaction results in elevated plasma concentrations, increasing the risk of serious peripheral ischemia and acute ergot toxicity (ergotism). Prohibited medicines include specific macrolide antibiotics (e.g., erythromycin, clarithromycin), HIV protease inhibitors (e.g., ritonavir, nelfinavir), and azole antifungals (e.g., ketoconazole, itraconazole).

The product is also contraindicated with other ergot-type drugs and 5-HT1 receptor agonists (triptans) due to pharmacodynamic interaction. Combining these agents causes additive vasoconstrictive effects, increasing the risk of prolonged vasospasm. A mandatory 24-hour separation is required between administration of Cafergot Tablets and these triptan or other ergot-type medicines.

Other Constraints

The risk of drug accumulation is heightened in patients with hepatic impairment due to compromised metabolic clearance. Additionally, regulatory documents note that substances like Grapefruit or Grapefruit Juice may inhibit the CYP3A4 enzyme and contribute to increased ergotamine exposure.

Dual-Action Constriction of Cranial Blood Vessels

The physiological action is achieved through coordinated molecular mechanisms targeting vascular tone. The Ergotamine component acts as a partial agonist on Serotonin mathbf5- HT1 B receptors, causing the contraction of abnormally dilated extracerebral blood vessels. This effect is supported by the Caffeine component, which acts as an antagonist against Adenosine mathbfA1 and mathbfA2 A receptors, thereby removing a key physiological signal that promotes blood vessel relaxation. This combined molecular cascade causes the constriction of dilated extracerebral blood vessels. This sustained contraction reduces the pulsatile flow in the extracerebral vasculature.

---

Modulation of Trigeminal Nociceptive Signaling

Beyond its vascular effects, Ergotamine also engages mathbf5- HT1 D receptors located on the terminals of the trigeminal nerve. Activation of this receptor subtype leads to the presynaptic inhibition of the release of pro-inflammatory signaling molecules, such as CGRP. This modulation inhibits neuropeptide release and the corresponding inflammatory cascade.

---

Non-Selective Systemic Activity and Bioavailability Synergy

The overall physiological profile is influenced by two critical factors: the non-selective agonism of Ergotamine on mathbfalpha -Adrenergic receptors can extend the vasoconstrictive effect to systemic and peripheral vessels, representing a mechanistic constraint. However, Caffeine also provides a crucial functional synergy by enhancing the oral absorption of Ergotamine, accelerating the rate of receptor engagement. This dual intervention shapes the intensity and persistence of the resulting physiological change.

The administration of Cafergot Tablets is characterized by its use strictly as an intermittent acute therapy. The medication is available in two primary forms for delivery: the oral tablet (1 mg Ergotamine, 100 mg Caffeine) and the rectal suppository.

Administration for Acute Episodes

The core principle of use is to initiate treatment at the first sign of a vascular headache attack. The adult regimen for the oral tablet is described as beginning with an initial dose of two tablets. If relief is not achieved, an additional one tablet may be taken every 30 minutes.

Usage is subject to specific limits. The total dosage for any single acute attack is restricted to not exceed six tablets (6 mg Ergotamine). Furthermore, the total cumulative intake across a longer time frame is limited; administration is limited to no more than ten tablets within any seven-day period. This restriction is intended to prevent the drug’s use as a chronic daily medication.

Usage Context and Population Rules

The established pattern of use is as-needed, and chronic daily administration is not permitted. The tablets may be taken with or without food, though prompt administration remains the priority. The use protocol also restricts co-administration with other vasoconstrictors.

Regarding specific patient populations, the safety and effectiveness of the medication have not been established in pediatric patients, and use is generally restricted for patients with severe hepatic or renal impairment.

Research Evidence / Overview of Studies for Cafergot Tablets

---

Evidence for Use in Acute Migraine Headaches

Research has explored the agent Cafergot (ergotamine tartrate and caffeine) for acute migraine headaches. The evidence base includes older Randomized Controlled Trials (RCTs) and studies comparing it against other medicines used for migraine. These studies monitored short-term outcomes related to physical discomfort in the populations studied. Researchers tracked pain measurements and patient-reported outcomes describing perceived discomfort related to associated symptoms and functioning. Comparative studies reported patterns related to the time required for headache changes, though the findings were mixed. Certainty remains low for some aspects, as the foundational data relies heavily on older studies not always designed to modern trial criteria.

---

Evidence for Use in Other Vascular Headaches

Cafergot was evaluated in research exploring severe, throbbing head pain categorized broadly as vascular headaches. Available research for these conditions, characterized by fluctuating or episodic manifestations, comes primarily from Historical Clinical Use Documentation and older observational reports. The research examined measurements related to interrupting or terminating an existing headache episode. However, dedicated modern clinical trials across different classifications are limited, and data for certain groups remain insufficient.

---

Research Gaps and Patient Groups

The overall evidence quality contributes to a coarse grading of evidence level for its primary indication. A key limitation is the lack of modern, dedicated, placebo-controlled RCTs adhering to contemporary standards. Furthermore, the long-term effects are not fully established regarding sustained impact, as acute treatment studies focus on short-term outcomes. The research record focuses predominantly on the general adult populations studied. Evidence is limited in both pediatric and geriatric patients, and certainty remains low for appropriate use in these groups.

Key Studies & References

1. Ergotamine and Caffeine: MedlinePlus Drug Information (NIH/NLM)
2. Product Monograph: Cafergot (Ergotamine Tartrate and Caffeine) Tablets (Health Canada)

Common questions about Cafergot Tablets (FAQ)

---

Q: Why does the packaging or literature mention a maximum weekly limit for the tablets?

Regulatory documents state that this medication is only intended for use as an intermittent, acute treatment and is not meant for daily or long-term chronic use. The weekly limit is established because official product labeling dictates use strictly as an intermittent, acute treatment. Long-term continuous use or exceeding the prescribed limits has been associated with serious risks, including the potential for fibrotic complications and acute ergot toxicity.

---

Q: Is it normal to feel tingling or coldness in the hands or feet after taking this medicine?

Tingling (paresthesia), numbness, and coldness in the hands or feet are reported side effects of this medication. These symptoms are listed as side effects in the official safety profile. Because they may sometimes indicate serious complications related to blood vessel constriction, patients should be aware of these potential effects.

---

Q: Does Cafergot have a risk of dependence or addiction with long-term use?

The official product labeling advises against long-term, continuous use. If the medication is used too frequently over time, there is a risk of developing a medicine overuse headache. This condition is characterized by a reliance on the drug that can lead to headaches becoming chronic.

---

Q: Can Cafergot interact with nicotine or smoking products?

Yes, official safety information indicates that nicotine may interact with Cafergot. Nicotine can enhance the medication's effect of narrowing blood vessels, potentially increasing the risk of certain side effects. Official safety information indicates that patients who use nicotine products should be monitored, and any symptoms of poor circulation should be noted.

---

Q: Can taking Cafergot cause extreme fatigue or drowsiness?

While not the most common adverse reaction, official safety reports list drowsiness (somnolence) as a reported side effect. Other reactions like weakness and vertigo (a spinning sensation) have also been reported and may contribute to a general feeling of tiredness or reduced alertness.

---

Q: Is Cafergot safe for women who are breastfeeding?

This medication is officially contraindicated for use while breastfeeding. The reason is that both active ingredients are known to pass into human milk. This poses a serious risk to the nursing infant, potentially causing adverse effects like vomiting, diarrhea, weak pulse, and unstable blood pressure.

---

Q: What serious side effects related to the heart have been reported with Cafergot?

Official warnings mention several serious cardiac effects due to the drug’s vasoconstrictive action. These include myocardial ischemia (a condition related to a heart attack), precordial distress (chest pain), and changes in heart rhythm such as unusually fast or slow heartbeat. Long-term continuous use can also rarely lead to fibrotic thickening of heart valves.

---

Q: Does Cafergot interact with any medications that affect the CYP3A4 enzyme?

Yes, regulatory documents emphasize the risk of interaction with medicines that affect the CYP3A4 liver enzyme. It is strictly contraindicated with potent CYP3A4 inhibitors, as this can increase drug levels and toxicity. Furthermore, drugs that act as CYP3A4 inducers (which lower the drug level) may reduce the effectiveness of Cafergot.

---

Q: Are there any reported allergic reactions to the ingredients in Cafergot, such as the yellow dye?

Yes, official labeling notes that some formulations contain tartrazine (FD&C Yellow No. 5), which may cause allergic reactions, including symptoms like bronchial asthma, in sensitive individuals. Official labeling states that known allergies to drug components should be discussed with a healthcare professional.

---

Q: What kind of studies or research support the use of Cafergot for migraines?

The medication is approved by the FDA for the abortive treatment of vascular headaches, including migraines and cluster headaches. This indication is supported by clinical efficacy data, including studies that have shown the medication is effective in reducing the severity and duration of headache symptoms.

---

Q: What should be done if Cafergot does not relieve my headache pain?

Regulatory instructions define strict limits on the maximum number of tablets that may be used for a single attack or within a seven-day period. If a headache persists after reaching these official limits, the patient's healthcare professional should be contacted.

---

Q: Does Cafergot have an effect on kidney or liver function?

Official product information states that the drug is contraindicated for use in patients with severe liver or kidney impairment due to the risk of drug accumulation. This necessitates monitoring for patients with milder impairment, indicating the drug's impact on these organs.

---

Q: Are there any warnings about using Cafergot and driving or operating machinery?

Reported side effects include dizziness, vertigo (spinning sensation), and drowsiness. Because these effects could potentially impair judgment or motor skills, caution is generally recommended regarding activities that require full attention, such as driving or operating machinery.

---

Q: Does the caffeine in the tablet contribute to the risk of side effects?

The caffeine component is a known central nervous system stimulant. While it is included to enhance the absorption of ergotamine, using the tablets alongside excessive external caffeine sources (such as coffee or chocolate) may increase stimulant-related side effects like nervousness, shakiness, or a fast heartbeat.

---

Q: What are the rare but serious risks associated with blood flow issues from Cafergot?

The most serious risks are linked to severe blood vessel constriction. These include ischemia (a lack of blood flow) which can manifest as conditions like gangrene or the absence of a pulse. These complications can ultimately lead to major events such as cerebral ischemia (stroke) or myocardial ischemia (heart attack).

---

Q: How does the combination of ergotamine and caffeine work better than either ingredient alone?

The combination of ergotamine and caffeine is used to enhance the therapeutic effect. Regulatory studies show that the caffeine component is crucial because it significantly enhances the oral absorption and bioavailability of the ergotamine, allowing it to reach effective levels more quickly.

---

Q: Does Cafergot lose effectiveness if it is used too frequently?

Frequent use is associated with a specific safety concern. The product label warns that using the drug for long periods or too often can lead to a phenomenon called medicine overuse headache, where the drug can stop relieving the headache and instead contribute to the pain becoming chronic.

---

Q: Are there any vision changes reported as a side effect of Cafergot?

Yes, official reports list vision changes as potential side effects. These include general visual impairment and blurred vision. More serious visual effects, such as a temporary loss of vision, have also been reported, potentially resulting from the vasoconstrictive effects on the eye’s blood supply.

---

Q: Is it normal for my migraine to feel worse a few days after stopping Cafergot?

If the medication has been used for prolonged periods, withdrawal headaches have been reported upon discontinuation. Worsening or persistent headaches after stopping the medication should be noted.

How to Store and Dispose of Cafergot Tablets?

Cafergot (ergotamine tartrate and caffeine) tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The official labeling strictly mandates that the product be kept from freezing.

Storage Conditions

Requirement	Specific Condition
Temperature Range	20 C to 25 C
Environmental Protection	Protect from light and moisture
Container Rule	Store in a tight, light-resistant container

Additionally, for safety, the medication must be kept out of the reach of children. Unused or expired tablets must be properly disposed of; consult a healthcare professional, such as a pharmacist, for guidance on local disposal protocols. Regulatory guidance advises against flushing medicines down the sink or toilet unless explicitly stated.